This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Ambulatory oxygen therapy in COPD

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • long-term oxygen therapy (LTOT)
    • clinicians should be aware that inappropriate oxygen therapy in people with COPD may cause respiratory depression
    • LTOT can be defined as oxygen used for at least 15 hours per day in chronically hypoxaemic patients
      • chronic hypoxaemia is defined as a PaO2 <=7.3kPa or, in certain clinical situations, PaO2 <=8.0kPa
      • patients with stable chronic obstructive pulmonary disease (COPD) and a resting PaO2 <=7.3kPa should be assessed for LTOT which offers survival benefit and improves pulmonary haemodynamics
      • consider LTOT if patients have a PaO2 above 7.3 and below 8 kPa when stable, if they also have 1 or more of the following: secondary polycythaemia, peripheral oedema, pulmonary hypertension(2)
      • LTOT should be ordered for patients with resting hypercapnia if they fulfil all other criteria for LTOT (2)
    • oxygen concentrators should be used to provide the fixed supply at home for long-term oxygen therapy
    • patients should be warned about the risks of fire and explosion if they continue to smoke when prescribed oxygen
  • ambulatory oxygen therapy
    • people who are already on LTOT who wish to continue with oxygen therapy outside the home, and who are prepared to use it, should have ambulatory oxygen prescribed
    • ambulatory oxygen therapy should be considered in patients who have exercise desaturation, are shown to have an improvement in exercise capacity and/or dyspnoea with oxygen, and have the motivation to use oxygen
    • ambulatory oxygen therapy is not recommended in COPD if PaO2 is greater than 7.3 kPa and there is no exercise desaturation
    • ambulatory oxygen therapy should only be prescribed after an appropriate assessment has been performed by a specialist. The purpose of the assessment is to assess the extent of desaturation, and the improvement in exercise capacity with supplemental oxygen, and the oxygen flow rate required to correct desaturation
    • small light-weight cylinders, oxygen-conserving devices and portable liquid oxygen systems should be available for the treatment of patients with COPD
    • a choice about the nature of equipment prescribed should take account of the hours of ambulatory oxygen use required by the patient and the oxygen flow rate required
  • short-burst oxygen therapy
    • short-burst oxygen therapy should only be considered for episodes of severe breathlessness in patients with COPD not relieved by other treatments
    • short-burst oxygen therapy should only continue to be prescribed if an improvement in breathlessness following therapy has been documented
    • when indicated, short-burst oxygen should be provided from cylinders
  • non-invasive ventilation (NIV)
    • adequately treated patients with chronic hypercapnic respiratory failure who have required assisted ventilation (whether invasive or non-invasive) during an exacerbation or who are hypercapnic or acidotic on LTOT should be referred to a specialist centre for consideration of long-term NIV

For more detailed guidance then see the full BTS guideline.

Reference:

1. National Institute for Health and Clinical Excellence (NICE) 2018. Chronic obstructive pulmonary disease in over 16s: diagnosis and management.

2. Hardinge M, Annandale J, Bourne S, et al. British Thoracic Society guidelines for home oxygen use in adults. Thorax2015;70:i1-i43.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.